A 2025 cross-sectional observational study of nearly 350 women with premature ovarian insufficiency (POI) revealed that almost 30% experienced depressive symptoms, far higher than the general population—highlighting a hidden mental health crisis linked to early menopause.

A mouse study presented at ENDO 2025 by University of Michigan researchers found that tirzepatide (marketed as Mounjaro/Zepbound) caused ~20% weight loss in obese mice and dramatically slowed breast tumor growth, linking fat loss directly to improved cancer outcomes.

A 2021 review in Nutrients by Smith‑Ryan et al. highlights that women have 70–80% lower natural creatine stores than men, making supplementation especially impactful for their health and performance.